Code | CSB-EP005061HU |
MSDS | |
Size | $224 |
Order now | |
Image | |
Have Questions? | Leave a Message or Start an on-line Chat |
To make this Recombinant Human CDK2 protein, the CDK2 gene was isolated at first and cloned into an expression vector. CUSABIO has built a mature recombinant protein platform. This Recombinant Human CDK2 protein was developed in the platform. It was expressed in E.coli at the region of 1-298aa of the Human CDK2 protein. N-terminal 6xHis tag was fused with the expression vector for affinity and purification purposes. The purity is 90%+ determined by SDS-PAGE.
Cyclin-dependent kinase 2 (CDK2) is a member of the larger cell cycle regulating CDK family of kinases, activated by binding partner cyclins as its name suggests. In mitotic cells, CDK2 is activated by phosphorylation and binds to E-type cyclins to progress from G1 into S phase, then subsequently binds A-type cyclins in S phase to advance the cell cycle. In particular, it was thought that CDK2/cyclin E complexes were necessary for the phosphorylation of retinoblastoma (RB) protein and the release of E2F transcription factors to initiate S phase and DNA synthesis. Further analysis reveals that the CDK2 substrate RB remains phosphorylated, even at sites previously thought to be specific to CDK2, suggesting a compensatory mechanism by another kinase. During the last two decades, CDK2 inhibitors have not been developed for contraception but instead predominantly to treat cancer. Multiple CDK2 inhibitors have entered clinical trials, none have been approved by the Food and Drug Administration.There are currently no reviews for this product.